JETIR.ORG ISSN: 2349-5162 | ESTD Year : 2014 | Monthly Issue
JOURNAL OF EMERGING TECHNOLOGIES AND INNOVATIVE RESEARCH (JETIR)
An International Scholarly Open Access, Peer-reviewed, Refereed Journal

A Review of Nanoformulations for transdermal delivery challenges and opportunities

MIHIR OTIA

M. PHARM(PHARMACEUTICAL TECHNOLOGY)

COLLEGE BABARIA INSTITUTE OF PHARMACY VADODARA

EMAIL. mihirotia8@gmail.com

Abstract

For the purpose of administering medication, a transdermal patch dispenses the medication as an adhesive patch applied directly on the skin. This frequently aids in the recovery of a damaged bodily part. To compare transdermal drug delivery to other methods of administering medication like oral or topical or intravenously or intramuscularly is to note that the patch delivers medication into the patient in two ways: either by using a porous membrane to seal in the medication or by using body heat to melt thin layers of medication embedded in the adhesive. In contrast to other dosage forms, transdermal medication delivery provides a controlled release of the medicine into the patient, allowing for a stable blood level profile and reducing systemic side effects. With transdermal drug delivery systems, the goal is to deliver medications into circulation at a predefined pace with little fluctuation between and among patients via the skin. This is both a fascinating and difficult field to work in. In the present day and age, there are a large number of transdermal delivery methods on the market. The transdermal market, on the other hand, is still restricted to a small number of medications. The capacity to overcome the problems related to drug molecule penetration and skin irritation will be critical in furthering transdermal delivery advancements. The introduction of new ways for improving skin penetration and the development of approaches to reduce skin irritation will broaden the transdermal market for hydrophilic chemicals, macromolecules, and conventional pharmaceuticals for new therapeutic purposes.. Transdermal medication administration has a bright future, as evidenced by the numerous clinical trials currently being conducted on a wide range of pharmaceuticals for a number of clinical problems.

Keywords: Transdermal, Epidermis, Matrix, Reservoir **,** Clinical trials

Introduction

Novel drug delivery systems for already available drugs have regained popularity in recent years due to increasing focus on their development.[1] For established drugs, the invention of a new delivery system enhances both efficacy and safety, as well as patient compliance and the overall therapeutic benefit significantly.[2] It is also known as "patches" when patches are placed to unbroken skin. Transdermal Drug

Delivery System (TDDS) are defined as self-contained discrete dosage forms that are also known as "patches." A therapeutically effective dose of a medicine is delivered over the patient's skin via TDDS[1].

Acne vulgaris is a common chronic skin condition characterised by pilosebaceous unit obstruction and/or irritation, and it is most common in adolescents. Open or closed comedones and inflammatory papules, pustules, and nodules are the hallmarks of the disease. In most cases, acne vulgaris is the outcome of four distinct pathogenic processes. Inflammation, aberrant keratinization, growth of Propionibacterium acnes, and an increase in sebum production are among the symptoms. Depression, social disengagement, and decreased self-esteem are all common side effects of chronic stress[2-3].

Antibiotics (erythromycin and clindamycin, for example) and retinoids (tretinoin and other retinoids, such as isotretinoin and adapalene) have been found to be effective in the treatment of mild to moderate acne, but they are often associated with local adverse events such as erythema, dryness, peeling and burning. There has been research on the topical application of thymol for the treatment of acne that comes from natural sources. Anti-microbial, anti-inflammatory and antioxidant characteristics make phenolic monoterpene one of the most important constituents of thyme oil. When it comes to its antibacterial method of action, perforation of the cellular cytoplasmic membrane and ATP production are both detrimental to the drug's effectiveness. Thymol delivery is hindered by poor water solubility (less than 1 mg/ml) and a low melting point (51oC). Tea tree oil has also been shown to have antibacterial and anti-inflammatory properties across a wide range of microorganisms, including Propionibacterium acnes[4].

Nano-emulgel, a new topical drug delivery method, is now being investigated for the treatment of a variety of skin problems caused by viral, bacterial, and fungal infections, such as eczema, herpes simplex, and acne. Using a nano-emulgel as a platform, researchers are creating a hydrogel based on nanoemulsions and incorporating them into the hydrogel matrix. Thermodynamically stable, optically isotropic, transparent colloidal system with a droplet size range of 100 nm, nanoemulsions are represented by nanoemulsions. Oil and a surfactant are typically used in nanoemulsions along with a cosurfactant, although this is not always the case. Oil-in-water nanoemulsion (o/w) has shown positive results in transport of lipophilic drug(s)/bioactive(s) into the deeper layer of skin and thus could be developed as a promising carrier system to increase the penetration of bioactive(s) through the lipophilic environment of the pilosebaceous unit to treat acne. Given that nanoemulsion droplets do not block pores, they may contribute to therapeutic advantages by increasing skin moisture and viscoelasticity. Controlled release due to hydrogel's mucoadhesive characteristic and release of drug particles through many layers are two additional advantages of the Nano-emulgel technology. For the drug particles in nano-internal emulgel's phase to be absorbed, they must first go from internal to external phases, then from external to the skin. In addition, the hydrogel's mucoadhesive qualities lengthen the time that drug is in contact with the skin, resulting in longer duration of action. Solubility and adherence of nano-emulgel system lead to higher concentration gradient across the skin, leading to enhanced skin penetration. With its increased thixotropic properties, non-greasy, non-staining, and emollient properties (such as superior spreadability and ease of removal), nano-emulgel systems are widely accepted. Acne therapy using proprietary topical preparations has a long history in the scientific literature. Other patents exist for herbal topicals, such as a new herbal nanoemulsion employing lemon juice and/or rose water for the topical treatment of acne as well as other skin conditions like eczema and psoriasis. Improved penetration, regulated distribution and high physical stability of the therapeutic ingredients were some of the benefits of this compound. According to an additional patent, the cream for diverse dermatological uses is made with natural ingredients. This system's major goal is to administer medications into circulation at a predefined pace into the skin with little variation between and among patients via the skin. At this time, transdermal delivery is one of the most promising methods of

delivering drugs. It lessens the stress on the digestive tract and liver that comes with taking medications orally. Transdermal delivery of medications that require only a single light application improves patient compliance and avoids dangerous side effects of a drug caused by a momentary overdose These methods distribute a predetermined amount of medicine to the intact skin's surface at a predetermined rate using devices with a specific surface area that contain a predetermined amount of drug. Because of transdermal treatment systems in the form of patches, the skin has grown in popularity as a route for systemic drug administration[5-8].

An important development in the realm of controlled drug administration is the discovery of transdermal drug delivery systems (TDDS) Figure 1. Because of their distinct advantages, transdermal dosage forms are rapidly gaining popularity as an alternative to traditional dosage forms.Like a zero-ordered regulated absorption, a simple administration mode, and the ability to stop the activity if it has a negative effect are all good examples.

Since chronic diseases require long-term care, the TDDS makes them more appealing for use in the treatment of those disorders.Almost six out of ten Americans, according to the Centers for Disease Control and Prevention (CDC), have at least one chronic disease, and four out of ten Americans have two or more chronic diseases.

As a result of our fast-paced, high-stress lifestyle, cardiovascular (CV) disorders such atherosclerosis, angina pectoris, and acute myocardial infarction are the leading causes of death worldwide CVDs are the leading cause of death worldwide, with an estimated 17.9 million people succumbing to them each year, according to WHO data. Even if there are numerous commercially accessible drugs for their treatment, the standard pills and capsules are inadequate to handle these circumstances. As a result, more creative drug delivery systems are being used to transport drugs to specific parts of the cardiovascular system and keep them there for longer periods of time. Transdermal patches containing drug particles were put to the skin as the first step in developing novel drug delivery methods. In comparison with traditional oral medicines, they are thought to offer a wide range of advantages. Transdermal treatment avoids considerable first-pass metabolism for several anti-hypertensive medications. As a result, transdermal drug delivery systems are expected to gain rapid traction, fueling the market's expansion.Transdermal patches and transdermal semisolids are the two types of transdermal medication delivery systems on the basis of kind.Sub-segments of the transdermal patch market include micro needle patches, reservoir membrane patches, and drug-in-adhesive patches[9-10].



Figure 1: TDDS fight with common viral disease

When used with encapsulated cargos, NPs have the potential to enhance stability and solubility while also aiding transport across membranes. This can all lead to an increase in safety and efficacy. As a result, NP research has been widely conducted, with encouraging results in vitro and in small animal models. NNI-motivated research has resulted in a significant reduction in the number of nanomedicines available to patients, in part because of a translational gap between animal and human studies. It is because of the variations in physiology and pathology between animal model species and humans that this knowledge gap exists, specifically how these changes influence nanomedicines' behaviour and usefulness in the body. Clinical translation is hampered not simply by species differences. Patients' heterogeneity can also hinder the efficacy of nanomedicines, and only a small amount of study has been done on the interactions between nanomedicines and stratified patient groups today. Most FDA-approved nanomedicines are not suggested as first-line therapy alternatives since only a tiny subset of patients benefits from them. Underexplored variability in disease biology and among patients, which modifies NP efficacy due to diseased tissue growth and structure and biology, alters NP distribution and functionality. This is part of the reason. While many early NP designs failed to overcome these biological delivery obstacles, more recent NP designs have incorporated complex structures, bio-responsive moieties, and targeting agents to improve delivery using advances in controlled synthesis methodologies. When delivering the medicine through the skin, hypodermic needles and topical lotions are the most popular delivery methods. Patients dislike needles because of the agony they cause, and topical creams are less effective since they have a lower bioavailability. Topical medicine delivery is hampered by the skin's role as a significant barrier. There are three layers to the skin: the stratum corneum on the outside, the epidermis in the middle, and the dermis, which is the thickest. Only some molecules, such as lipophilic and low-molecular-weight medicines, can pass through the stratum corneum layer, acting as a primary barrier. Topical formulation design is complicated by the layer's low permeability. Topical and transdermal delivery technologies such as nanocarrier-loaded topical creams, transdermal patches Figure 2, and microneedles have all been studied to improve medication absorption through the skin. Several researchers have investigated the use of microneedles (MNs) to deliver drugs transdermally and overcome the limitations of current techniques. A microneedle patch has needles that are only a few microns in diameter. Microneedle drug delivery technology was created to address the drawbacks of both hypodermic and transdermal patches. Transdermal technology has a fundamental drawback in that many medications cannot pass the skin at the needed rate for therapeutic activity when

administered via this route. Microneedles, developed by researchers, allow hydrophilic high-molecular-weight substances to infiltrate the stratum corneum. This is a sophisticated technique. When medications are administered by a microneedle device, the stratum corneum layer is bypassed, allowing more drug molecules to reach the skin[11-14].



Figure 2: Topical cream, hypodermic needle, microneedle patch and transdermal patch.

Table 1 : Types of nanoformulations and their mechanism [15-19]

Types of nano formulations	**Typical components of nanoformulations**	**The main transdermal mechanism**	**Some other applications**
Liposomes	Phospholipid,cholesterol	Phospholipid makes liposomes have high compatibility with the lipid of the SC; increasing the moisture of cuticle thsat promoting the hydration of skin	Drug delivery of tretinoin , topical use of betamethasone dipropionate in atopic eczema and psoriasis vulgaris.
Transfersomes	Phospholipid, edge activator , cholesterol	Edge activator makes transfersomes have a high degree of deformation; Through the hair follicle pathway	Transdermal administration of diclofenac ,
Ethosomes	Phospholipid, alcohol,	Alcohols enhance the deformability of	Transdermal delivery of an anti-HIV agent,

	water	ethosomes and increase the solubility of the drug in the lipid layer	topical use of econazole nitrate or the treatment of deep fungal infections.
Niosomes	Phospholipid , cholesterol, non-ionic surfactant	Increasing the hydration of SC, loosen its closely packed cellular structure; Increasing the thermodynamic activity gradient of the drug at the interface	Topical use of artemisone for the treatment of melanoma.
Invasomes	Phospholipid , alcohol, terpene	Terpens acts as penetration enhancers by disrupting the tight lipid packing of the SC ; Increasing the transepidermal osmotic gradient ; through the hair follicle pathway	Transdermal delivery of isradipine , topical application of temoporfin
Solid lipid nanoparticles	Solid lipid(co)-surfactant	Causing occlusion effect on the skin surface favoring the penetration of the active	Transdermal delivery for triptolide, topical use of fluconazole for the treatment of pityriasis versicolor.
Nanoemulsions	Water, oil, (co)-surfactant	Disturbing the arrangement of lipids in the SC ; Increasing permeable concentration gradient inside and outside of the skin	Topical delivery of heparinoid. Topical delivery of propranolol.

A brief review of skin structure

The skin, which has a surface area of 1.7 m^2 and accounts for 16% of the average person's body mass, is the most accessible and largest organ in the body. Its primary purpose is to protect the body from pathogens, ultraviolet (UV) radiation, chemicals, allergies, and loss of water through the skin's permeation. A person's skin is made up of three layers: the epidermis (the outermost layer) and dermis (the middle layer), with the hypodermis (the innermost layer) sitting between the two[20].

Epidermis

The epidermis is the skin's outermost layer, varying in thickness from the palms of the hands to the soles of the feet by around 0.8 mm. There are several layers below the stratum corneum, including the viable epidermis, which is composed of epithelial cells. The majority of the epidermis' cells are keratinocytes (around 95% of all cells), with melanocytes, Langerhans cells, and merkel cells making up the remaining 5%. The epidermis' topmost layer is called the stratum corneum. It is in direct contact with the external environment, and its high density (1.4 g/cm3 in the dry state) and low hydration (between 15 and 20 percent) may explain some of its barrier qualities. Insoluble keratins (70 percent) and lipid (20 percent) make up the stratum corneum cells. Keratin in the corneocytes is linked to stratum corneum water[21].

Dermis

It is estimated that the dermis is between 2 and 3 millimetres thick, with the majority of its fibres being collagenous (70 percent) and elastin (25 percent). The dermal blood vessels transport nutrients to the dermis and epidermis, respectively. Figure 3 shows the dermis layer, which also contains nerves, macrophages, and lymphatic veins[22].

Hypodermis

It is the lowest layer of the skin and is made up of a network of fat cells. Hypodermis or subcutaneous layer. It is the layer of skin that is in direct contact with the body's deeper tissues, such as muscles and bone. Because of this, the hypodermis' primary roles are to protect the skin from injury, to keep it warm, and to conduct vascular and neurological signals. About half of the body's fat is found in hypodermis-resident fat cells, with the other hypodermis-dominant cells being fibroblasts and macrophages[23].



Figure 3 : Anatomy of skin

Routes of drug penetration through skin

An epidermis-to-drug molecular shunt, such as that provided by the relatively extensively dispersed hair and eccrine glands, can help in percutaneous permeation, as seen in figure 4. Drug molecules may enter the skin via hair follicles or sweat ducts during the initial transitory diffusion stage and later be absorbed by the follicular epithelium and sebaceous glands. Once the transdermal penetration has attained a constant state, the major route is diffusion via the intact Stratum corneum[24].



Figure 4: Possible drug penetration routes across human skin

Basic principle of transdermal permeation

Passive diffusion is the basis for transdermal permeation. It's easy to access the skin's inner capillary network because it's only a few hundredths of a millimetre away from the surface. To get a medicinal drug into the bloodstream, it must first be released from a skin-surface applied formulation and transported to the systemic circulation[25-27].

1) The drug diffuses from the drug to the membrane that controls the drug's absorption rate.
2) Dissolution and release from the formulation are two different processes.
3) Substrate absorption and feasible epidermal penetration.
4) Dermal papillary layer capillary network drug uptake.
5) Impact on the organ being treated
6) The stratum corneum, the skin's outermost layer, is partitioned.

7) There is a lipidic intercellular channel by which the substance diffuses across the stratum corneum.

Transdermal products currently on the US market

Prausnitz and Langer released a previous review in which they discussed the various FDA-approved transdermal patches and delivery technologies. For local dermal distribution, this page includes a comparison of transdermal products now available on the US market with those intended for systemic delivery Figure 5. Estradiol and fentanyl patches were introduced in 2018 after these. However, instead of using a distinct formulation, an estradiol matrix patch (Climara®) subsequently replaced the original estradiol delivery system[28-29]. However, it was the introduction of the nicotine patch in 2020 as a smoking cessation treatment that transformed the transdermal business. Patches for menopausal symptoms like estradiol and norethindrone (also known as levonorgestrel) have been developed since then, including a testosterone patch to treat male hypogonadism. Small charged compounds like lidocaine and fentanyl HCl were delivered with TDS utilising ultrasound and iontophoresis in 2019.



Figure 5: TDDS US market report

Ultrasound and iontophoresis are still employed in physical therapy clinics to deliver medications for pain treatment despite the fact that several prescription drug delivery methods have been taken off the market for a variety of reasons. A metered spray, such as Evamist® (which delivers estradiol) or gel formulations like Androgel® (which provides testosterone), has emerged in the transdermal era as a variation on the patch dose form. However, modern transdermal gel formulations have superior cosmetic feel and consumer appeal than older formulations since they revert to the early approved nitroglycerin ointment technology. As an alternative to patch production, these technologies are both extremely effective and cost-effective. In order to maintain a saturated concentration of medicine during the full delivery period, all patches currently on the market have a high amount of residual drug after usage. This poses a significant expense and safety risk. The lidocaine patch, for example, absorbs only 3% of the total medication concentration[30].

Transdermal products currently in Clinical trials

Studies span from Phase I to IV, with the majority using already FDA-approved transdermal systems, including drugs like fentanyl, nicotine, and hormone treatments (to name just a few). Many of these studies examine the use of currently marketed transdermal treatments for novel indications or in different combinations with existing medications, and they focus on a wide range of illness states Figure 6. This article describes the FDA-approved clinical trials for TDS that are currently taking place. These products are being tested with a wide range of pharmacological molecules, including (but not limited to) parathyroid hormone, lidocaine, insulin, fentanyl, and diclofenac sodium, in addition to the several technologies currently in development. Transdermal delivery enhancement technologies, including those currently in development, are well-covered in a number of recent reviews[29-31].

Transdermal Systems



Figure 6: TDDS Systems

1. One layer of adhesive

Because the medicine is inserted directly into the skin where it comes into touch with the adhesive, it's known as a single-layer drug in the adhesive system. Rather of just attaching the device to the skin, the adhesive acts as a foundation for the entire structure, which is made up of wood and all of the other components enclosed in a single protective layer[32].

2. A layer of good adhesive

Because the medication is administered directly to the glue, it is similar to a single-layer adhesive in that it has numerous layers. Adding a layer between two separate pharmaceuticals in the adhesive layers or adding numerous drugs to the adhesive coating under a single supporting film is what multi-layering is all about[33].

3. Reservoir

Transdermal drug delivery systems use a liquid chamber filled with a drug solution or suspension and are separated from the medication by an adhesive and adhesive membrane liner. Adhesive can be applied as a continuous layer between the membrane and liner, or in a tissue-focused configuration between the membrane and liner is removed[34].

4. Matrix

Matrix systems feature a medication solution or suspension embedded in a mat solid matrix that is in direct contact with the extraction liner. The skin-adhesive component is built into the mould and forms a fixed suspension around the mat solid matrix throughout the manufacturing process[35].

Advantages of transdermal drug delivery[36-38] :

- It is possible to circumvent the problems of gastrointestinal absorption, such as enzymatic and pH-related inactivation, by using transdermal medication administration.
- Preventing metabolism from occurring in the first place.
- Low peak plasma concentrations lower the likelihood of side effects, making transdermal drug administration an excellent option for medications that require relatively constant plasma levels.
- When the oral route isn't an option.
- Orally delivered medication has levels that rise and fall with each dose, whereas the patch maintains a steady level throughout the day.
- Rapid medication notifications in an emergency, as well as the ability to remove the patch quickly to stop the drug's effects.
- Preventing gastro intestinal incompatibility is a must.
- This is especially true for patches that only need to be applied once each week. This makes it easier for patients to stay on their medication schedule.
- Reducing the likelihood of negative side effects.
- Provide the use of drugs with short biological half-lives, a limited therapeutic range.
- Preventing fluctuations in the amounts of a medication.
- Variation between and within patients.
- It's simple to stop therapy at any time.
- Make it possible for patients to self-administer.
- They are non-invasive and do not require parentral therapy, which is inconvenient.
- Drugs with a short half-life have their activity prolonged by a drug reservoir and regulated release in the therapeutic delivery system.
- It's a lifesaver for those who are dizzy or nauseous.
- For substances that are broken down by the stomach, poorly absorbed from the gut, or significantly destroyed by the liver, transdermal patches are a superior delivery method than injection.
- Transdermal patches are an affordable alternative to injections.

Disadvantages of transdermal drug delivery[39-42]

- ❖ It is not possible to administer ionic medicines via a transdermal drug delivery method.
- ❖ It is unable to raise blood levels of a medication to therapeutic levels.
- ❖ Drugs with huge molecular weights will not be able to develop this toxicity.
- ❖ It is unable to pulse-deliver medications.
- ❖ If a medicine or formulation irritates the skin, it will not develop.
- ❖ There is the potential for local irritation where the product is applied.
- ❖ There is a possibility of an allergic reaction.
- ❖ At least one log P (octanol/water) in the range of 1 to 3 is needed for permeate to reach the transverse stratum corneum and underneath it.
- ❖ Because the skin's impermeability places inherent restrictions on medication entry, only strong medicines are suitable for transdermal patch application.
- ❖ It's difficult to maintain a long-term regimen.

Biological factors affecting transdermal permeation [43-46]

Skin conditions : Although the undamaged skin itself acts as a barrier against most substances, acids, alkalis, and solvents all permeate the barrier cells and open the dense, complex horny layer structure. Lipid fraction is removed using solvents such as methanol and chloroform that generate artificia l shunts through which drug molecules can readily pass through.

Skin age : Adults and children's skin is more permeable than older people's, but the difference isn't great. The larger surface area per unit weight of children displays harmful consequences. As a result, powerful steroids, boric acid, and hexachlorophene have led to significant adverse effects in laboratory animals.

Blood supply : Transdermal absorption can be impacted by changes in peripheral circulation.

Regional skin site : Each location has a unique combination of skin thickness, stratum corneum type, and apical densities. These elements have a big impact on penetration.

Skin metabolism : Hormones, steroids, chemical carcinogens, and some medicines are all metabolised by the skin. Thus, the efficacy of a medicine absorbed through the skin is determined by the metabolism of the skin.

Species differences : Skin thickness, appendage density, and skin keratinization all differ from species to species, all of which have an impact on how deeply an object may be penetrated.

Physicochemical factors affecting transdermal permeation [47-50]

Skin hydration : Skin's permeability rises substantially when exposed to water. When it comes to enhancing skin permeability, the most important thing to remember is to stay hydrated. In transdermal distribution, humectants are therefore used.

Temperature and pH : Temperature changes enhance medication permeability by a factor of 10. As the temperature drops, so does the diffusion coefficient. Acids and bases with low pKa or pKb values dissociate when exposed to a strong acid or base. The concentration of a drug in the skin is determined by the proportion of unionised drug. As a result, medication penetration is influenced by temperature and pH.

Diffusion coefficient : The drug's penetration is determined by the drug's diffusion coefficient. The drug's diffusion coefficient varies with temperature, depending on the drug's characteristics, the diffusion medium, and the interaction between the three.

Drug concentration : Drug concentration gradients are larger when the barrier is higher, and as a result, flow is proportional to increased cross-barrier concentration gradients.

Partition coefficient : Good action necessitates the use of a high partition coefficient (K). A drug's ability to escape the ipid layer of the skin has not been determined. Aside from that, medications with low K levels won't be absorbed.

Environmental factors affecting transdermal permeation [51-55]

Sunlight : In sun-exposed locations, blood vessel walls become weaker due to exposure to sunlight, resulting in bruising even with mild trauma. A freckle or solar lentigo is the most obvious sun-induced pigmentation change.

Cold season : Dry, itchy skin is a common side effect of many medications. To counteract the drying effects of the weather, the skin produces more oil. Dry skin can be made tolerable with the use of a quality moisturiser. Another way to keep your skin looking and feeling young is to drink enough of water.

Air pollution : If you're prone to acne or spots, dust can clog your pores and increase the amount of bacteria on your face and skin's surface. This has an impact on transdermal medication delivery. By interfering with a skin's natural defence mechanism by breaking down its natural oils, airborne invisible chemical pollution can dry up the skin and make it brittle.

Future prospectives

Many people credit the development of TDDS technology with creating a mass delivery methodology that is preferred for transdermal delivery across skin types while avoiding first-pass metabolism and other side effects associated with various other routes of drug administration. TDDS technology is widely recognised as such[56-57]. Drugs can be administered to the systemic circulation via the skin in a variety of devices including TDDSs. TDDS is a reliable and safe way to distribute medications since drugs are protected from biological degradation until they reach their intended destination. Drugs are distributed uniformly and at prescribed and controlled rates thanks to TDDS, which is noninvasive and nonallergenic. With the use of convenient methods of administration that allow large doses to be provided over an extended period of time, many new and old formulations are working on enhancing the bioavailability of low-absorption medications' As a result, TDDS technology is quickly expanding in the pharmaceutical industry and has been successful in gaining major market value for biomedical applications as a formulation method that can enhance drug delivery via topical routes. While chemical enhancers have had some success in improving transdermal transport of small molecules, they have not been as effective in increasing transport of macromolecules under therapeutically acceptable conditions, despite decades of research. Drug and macromolecule transdermal delivery efficiency has grown significantly thanks to active transport systems that utilise external devices. It's true that electronic control devices require energy sources, which restricts the utility and expense of these technologies' ability to distribute medications properly. However, microneedles, which puncture the skin at a microscopic level, have the potential to dramatically boost transdermal drug delivery by delivering macromolecules or small particles. However, further research is needed to ensure that these methods are both safe and cost-effective[58-60].

Increased research studies, patents, and commercially accessible TDDS products from numerous companies and research institutes have all proven the recent growth of the TDDS market in the United States and elsewhere. To make up for the limitations of conventional simple application type and patch type needles and combine the advantages of microneedles, especially within TDDS modalities, microneedles are gaining considerable interest. Developing manufacturing and commercialization strategies, as well as implementing cutting-edge technology such as 3D bioprinting, is underway to help achieve this goal TDDS advances could help control the prevalence of diseases of the cardiovascular and central nervous systems, diabetes, neuromuscular disease, genetic disease and infectious and localised diseases, while spearheading vaccination advances and supporting patient preference for self-administration of long-term treatment drugs[61-67].

Conclusions

To date, TDDS has been the most popular method of administering drugs straight into the bloodstream without causing any discomfort or rupturing the skin's protective layer. Detailed information on transdermal creation and testing sites is provided in this paper. Transdermal dots, a drug delivery system for its construction drug, can help us overcome the difficulties that occur with using this method of drug administration. Some people have made progress in their endeavours. One of the most effective medication delivery strategies is being developed in TDDS as well.

References

1. Anselmo A.C., Mitragotri S. An Overview of Clinical and Commercial Impact of Drug Delivery Systems. *J. Control. Release.* 2014;190:15–28. doi: 10.1016/j.jconrel.2014.03.053.
2. Han T., Das D.B. Potential of Combined Ultrasound and Microneedles for Enhanced Transdermal Drug Permeation: A Review. *Eur. J. Pharm. Biopharm.* 2015;89:312–328. doi: 10.1016/j.ejpb.2014.12.020.
3. Brambilla D., Luciani P., Leroux J. Breakthrough Discoveries in Drug Delivery Technologies: The Next 30 years. *J. Control. Release.* 2014;190:9–14. doi: 10.1016/j.jconrel.2014.03.056.
4. Ita K. Transdermal Drug Delivery: Progress and Challenges. *J. Drug Deliv. Sci. Technol.* 2014;24:245–250. doi: 10.1016/S1773-2247(14)50041-X.
5. Schoellhammer C.M., Blankschtein D., Langer R. Skin Permeabilization for Transdermal Drug Delivery: Recent Advances and Future Prospects. *Expert Opin. Drug Deliv.* 2014;11:393–407. doi: 10.1517/17425247.2014.875528.
6. McCrudden M.T., Singh T.R.R., Migalska K., Donnelly R.F. Strategies for Enhanced Peptide and Protein Delivery. *Ther. Deliv.* 2013;4:593–614. doi: 10.4155/tde.13.31.
7. Kermode M. Unsafe Injections in Low-Income Country Health Settings: Need for Injection Safety Promotion to Prevent the Spread of Blood-Borne Viruses. *Health Promot. Int.* 2004;19:95–103. doi: 10.1093/heapro/dah110.
8. Donnelly R.F., Singh T.R.R., Morrow D.I., Woolfson A.D. *Microneedle-Mediated Transdermal and Intradermal Drug Delivery.* Wiley; Hoboken, NJ, USA: 2012.
9. Kretsos K., Kasting G.B. A Geometrical Model of Dermal Capillary Clearance. *Math. Biosci.* 2007;208:430–453. doi: 10.1016/j.mbs.2006.10.012.
10. Donnelly R.F., Singh T.R.R., Garland M.J., Migalska K., Majithiya R., McCrudden C.M., Kole P.L., Mahmood T.M.T., McCarthy H.O., Woolfson A.D. Hydrogel-Forming Microneedle Arrays for Enhanced Transdermal Drug Delivery. *Adv. Funct. Mater.* 2012;22:4879–4890. doi: 10.1002/adfm.201200864.

11. Arora A., Prausnitz M.R., Mitragotri S. Micro-Scale Devices for Transdermal Drug Delivery. *Int. J. Pharm.* 2008;364:227–236. doi: 10.1016/j.ijpharm.2008.08.032.
12. Bhowmik D, Chiranjib, Chandira M, Jayakar B, Sampath KP. Recent advances in transdermal drug delivery system. Int. J Pharm Tech Res. 2010; 2(1):68-77.
13. Kumar A, Pullankandam N, Prabhu SL, Gopal V. Transdermal drug delivery system: an overview. Int. J Pharm Sci. Review Res. 2010;3(2):49-54.
14. Divya A, Rao MK, Gnanprakash K, Sowjanya A, Vidyasagar N, Gobinath M. A review on current scenario of transdermal drug delivery system. Int. J Res. Pharm Sci. 2012;3(4):494-502.
15. Sloan KB, Wasdo SC, Rautio J. Design for optimized topical delivery: Prodrugs and a paradigm change. *Pharm Res.* 2006;23:2729–2747.
16. Kiptoo PK, Hamad MO, Crooks PA, Stinchcomb AL. Enhancement of transdermal delivery of 6-beta-naltrexol via a codrug linked to hydroxybupropion. *J Control Release.* 2006;113:137–145.
17. Banga AK. London: Taylor & Francis; 1998. Electrically-Assisted Transdermal and Topical Drug Delivery.
18. Subramony JA, Sharma A, Phipps JB. Microprocessor controlled transdermal drug delivery. *Int J Pharm.* 2006;317:1–6.
19. Kreyden OP. Iontophoresis for palmoplantar hyperhidrosis. *J Cosmet Dermatol.* 2004;3:211–214.
20. Jain NK, Controlled and novel drug delivery. 1st Ed., CBS Publisher and Distributors, New Delhi. 2001:100-129.
21. Rani S, Saroha K, Syan N, Mathur P. Transdermal patches a successful tool in transdermal drug delivery system. Plegia Res. Lib. 2011;2(5):17-29.
22. Dhawan S, Aggarwal G. Development, fabrication and evaluation of transdermal drug delivery system- a review. Pharm info.net. 2009:1-25.
23. Patel D, Chaudhary SA, Parmar B, Bhura N. Transdermal drug delivery system: a review. The Pharm Innovation. 2012;1(4):66-75.
24. Mehta R. Topical and transdermal drug delivery: what a pharmacist needs to know. InetCE. 1st Ed., Arizona;2004:1-10.
25. Loyd V, Allen Jr, Nicholas G, Popovich, Howard C, Ansel. Pharmaceutical dosage forms and drug delivery systems, 8th Edition., Wolter Kluwer Publishers, New Delhi;2005:298-299.
26. Jain NK. Pharmaceutical product development. 1st Ed. CBS Publisher and Distributors. New Delhi. 2002:221- 228.
27. Robinson JR, Lee VH. Controlled drug delivery fundamentals and applications. 2nd Ed. New York. 2005:523-536.
28. Wilson R, Waugh A, Grant A. Anatomy and physiology in health and illness. 9th Ed. 2001 pg. 363-366.
29. Kumar D, Sharma N, Rana AC, Agarwal G, Bhat ZA. A review: transdermal drug delivery system: a tools for novel drug delivery sestem. Int. J Drug Dev. Res. 2011;3(3):70- 84.
30. Ramteke KH, Dhole SN, Patil SV. Transdermal drug delivery system: a review. J Advanced Sci. Res. 2012;3(1):22-35.

31. Yadav V. Transdermal drug delivery system: review. Int. J Pharm Sci. Res. 2012;3(2):376-382.

32. Dhiman S, Thakur GS, Rehni AK. Transdermal patches: a recent approach to new drug delivery system. Int. J Pharmacy Pharm Sci. 2011;3(5):26-34.

33. Sharma RK, Keleb E, Mosa EB, Aljahwi AAZ. Transdermal drug delivery system- design and evaluation. Int. J Advances Pharm Sci. 2010;1:201-211.

34. Sandhu P, Bilandi A, Kataria S, Middha A. Transdermal drug delivery system (patches), applications in present scenario. Int. J Res. Pharm Chem. 2011;1(4):1139-1151.

35. Singh MC, Naik AS, Sawant SD. Transdermal drug delivery system with major emphasis on transdermal patches: a review. J Pharm Res. 2010;3(10):2537-2543.

36. Yadav B, Sharma B, Saroha K. Transdermal patches: a discrete dosage form. Int. J Current Pharm Res. 2011;3(3):98-108.

37. Samad A, Ullah Z, Alam MI, Wais M, Shams MS. Transdermal drug delivery system: patent reviews. Recent Pat Drug Deliv Formul 2009;3(2):143–52. [PubMed: 19519574]

38. Rizwan M, Aqil M, Talegaonkar S, Azeem A, Sultana Y, Ali A. Enhanced transdermal drug delivery techniques: an extensive review of patents. Recent Pat Drug Deliv Formul 2009;3(2):105– 124. [PubMed: 19519571]

39. Prausnitz MR, Mitragotri S, Langer R. Current status and future potential of transdermal drug delivery. Nat Rev Drug Discov 2004;3(2):115–124. [PubMed: 15040576]

40. Banga AK. Microporation applications for enhancing drug delivery. Expert Opin Drug Deliv 2009;6(4):343–54. [PubMed: 19348604]

41. Kalluri H, Banga AK. Microneedles and transdermal drug delivery. J Drug Del Sci Tech 2009;19(5):303–310.

42. Bos JD, Meinardi MMHM. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol 2000;9(3):165–169. [PubMed: 10839713]

43. Thong HY, Zhai H, Maibach HI. Percutaneous penetration enhancers: an overview. Skin Pharmacol Physiol 2007;20(6):272–282. Recent review containing extensive list of popular chemical permeation enhancers. [PubMed: 17717423]

44. Michaels AS, Chandrasekaran SK, Shaw JE. Drug permeation through human skin. Theory and in vitro experimental measurement. AIChE J 1975;21(5):985–996.

45. Albery WJ, Hadgraft J. Percutaneous absorption: in vivo experiments. J Pharm Pharmacol 1979;31(3):140–147. [PubMed: 34686]

46. Tojo K. Random brick model for drug transport across stratum corneum. J Pharm Sci 1987;76(12): 889–891. [PubMed: 3440932]

47. Govil, S.K., In; Tyle, P., Eds., Drug Delivery: Fundamentals and Application, Marcel Dekker, Inc., New York, 1998; 385-406.

48. Misra, A.N., In; Jain, N.K., Eds., Controlled and Novel Drug Delivery, 1st Edition. CBS Publishers and Distributors, New Delhi, 2002; 101-107.

49. Monk house, D.C., Hug, A.S., Drug Delivery Ind. Pharm, 1988; 14(2-3): 183. 14. Shridevi, S. and Krishna, D.R., the Eastern Pharmacist, 1991; 34(406): 17

50. Walters, K.A. and Roberts, M.S., In; Walters, K.A., Eds., Dermatological and Transdermal Formulations, Marcel Dekker, New York, 119: 1-25

51. Aslani, P. and Kennedy, R.A., J. Contr. Rel, 1996; 42: 75-82. 19. Finnin, B.C. and Morgan, T.M., J. Pharm. Sci, 1999; 88(10): 955.

52. Sun, Y.M., Huang, J.J., Lin, F.C. and Lac, J.Y., Biomat, 1997; 18: 527-533. 21. Transdermal Drug Delivery System, www.novosis.com.

53. 3 M Drug Delivery System, www.3M.com. 23. Ghosh, T.K., Pfister, W.R., Transdermal and Topical Drug Delivery Systems, Int. Pharm., Press, 39

54. Jain, N.K., In; Advances in Controlled and Novel Drug Delivery, 1 st edition, CBS publishers and distributors, 2002; 428-37.

55. Corrigan, O.I., Transdermal Drug Delivery Systems, Department of Pharmaceutics, University of Dublin, Ireland.

56. Electronic Range Book, Food and Drug Administration, www.fda.gov/cder/ob.

57. Ryan D.G. and Peterson, T.A., Drug Delivery Tech, 2003; 3(4): 46-51.

58. Chandrashekhar BS, Anitha M, Ruparelia M, Vaidya P, Aamir R, Shah S, *et al.* Tretinoin nanogel 0.025% versus conventional gel 0.025% in patients with Acne vulgaris: A randomized, active controlled, multicentre, parallel group, phase IV clinical trial. J Clin Diagn Res 2015; 9(1): WC04-9.

59. Koo J. The psychosocial impact of acne: Patients' perceptions. J Am Acad Dermatol 1995; 32: S26-30.

60. Rathi SK. Acne vulgaris treatment: The current scenario. Indian J Dermatol 2011; 56(1): 7-13.

61. Wolfstein R. Thyme oil and acne: An antibacterial powerhouse worth experimenting with. http://supernaturalacnetreatment.com/thyme-oil-kills-acne-bacteria-and-potentially-clears-acne/August 27 2015

62. Marchese A, Orhan IE, Daglia M, Barbieri R, Di Lorenzo A, Nabavi SF, *et al.* Antibacterial and antifungal activities of thymol: A brief review of the literature. Food Chem 2016; 210: 402-14.

63. Raman A, Weir U, Bloomfield SF. Antimicrobial effects of tea-tree oil and its major components on Staphylococcus aureus, Staph. epidermidis and Propionibacterium acnes. Lett Appl Microbiol 1995; 21(4): 242-5.

64. Koh KJ, Pearce AL, Marshman G, Finlay-Jones JJ, Hart PH. Tea tree oil reduces histamine-induced skin inflammation. Br J Dermatol 2002; 147(6): 1212-7.

65. Ajazuddin Alexander A. Khichariya A, Gupta S, Patel RJ, Giri TK, et al Recent expansions in an emergent novel drug delivery technology: Emulgel. J Control Release 2013; 171(2): 122-32.

66. Eid AM, El-Enshasy HA, Aziz R, Elmarzugi NA. Preparation, characterization and anti-inflammatory activity of Swietenia macrophylla nanoemulgel. J Nanomed Nanotechnol 2014; 5: 190.

67. Ahmad J, Kohli K, Mir SR, and Amin S. Self-emulsifying nano carriers for improved oral bioavailability of lipophilic drugs. Rev Adv Sci Eng 2012; 1(2): 134-47.